1-3 of 3
Stanford L. Peng, MD, PhD
Close
Sort by
Journal Articles

An Open Label Study of Alpn-101, a First-in-Class Dual CD28/ICOS Antagonist, in Subjects with Steroid-Resistant or Steroid-Refractory Acute Graft Versus Host Disease (aGVHD)

Jing Yang, PhD, Jan L. Hillson, MD, Kristi L. Manjarrez, Jennifer R. Wiley, DRSc, Gary D. Means, PhD, Stacey R. Dillon, PhD, Stanford L. Peng, MD,PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 372.
https://doi.org/10.1182/blood-2019-126034
Published: 2019
Journal Articles

Therapeutic Candidate Alpn-101, a Dual ICOS/CD28 Antagonist, Potently Suppresses Human/NSG Mouse Xenograft Graft Vs. Host Disease (GvHD) in a Dose Ranging Study and Reduces Disease Activity in a Mouse Model of Hemophagocytic Lymphohistiocytosis (HLH)

Stacey R. Dillon, PhD, Katherine E. Lewis, PhD, Katherine Verbist, PhD, Paige Tedrick, PhD, Sabrin Albeituni, PhD, Ryan Swanson, B.S., Lawrence S. Evans, B.S., Steven D Levin, PhD, Mark W. Rixon, PhD, Stanford L. Peng, MD, PhD, Kim E. Nichols, MD, Kristine M. Swiderek, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2037.
https://doi.org/10.1182/blood-2018-99-110001
Published: 2018
Journal Articles

"Switch" Transmembrane Immunomodulatory Proteins (TIPs) Consisting of High-Affinity PD-1 Extracellular Domains (PD-1 vIgDs) and Costimulatory Intracellular Domains Potently Enhance the Activity of TCR-Engineered T Cells

Steven D Levin, PhD, Hieu Nguyen, B.S., Joseph Kuijper, Rebecca P Wu, Ryan Swanson, B.S., Stanford L. Peng, MD, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2052.
https://doi.org/10.1182/blood-2018-99-117454
Published: 2018